Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

61.76USD
21 May 2019
Change (% chg)

$0.06 (+0.10%)
Prev Close
$61.70
Open
$62.27
Day's High
$62.27
Day's Low
$61.28
Volume
106,678
Avg. Vol
132,673
52-wk High
$65.55
52-wk Low
$29.17

Aguiar, Eric 

Dr. Eric Aguiar, M.D. serves as Independent Director of the Company. Dr. Aguiar has been a partner at Aisling Capital since January 2016 and prior to that was a partner at Thomas, McNerney and Partners, a healthcare venture capital and growth equity fund, since 2007. Prior to joining that firm, he was a Managing Director of HealthCare Ventures, a healthcare focused venture capital firm, from 2001 to 2007. Dr. Aguiar currently serves on the board of directors of Invitae Corporation (NYSE: NVTA). Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. Dr. Aguiar received his medical degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst. We believe that Dr. Aguiar's medical and finance background and experience as an investor in life science companies qualifies him to serve as a member of our Board.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 136,846
Long-Term Incentive Plans, USD --
All Other, USD 19,375
Fiscal Year Total, USD 156,221

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

247,770

Vlad Coric

3,855,660

James Engelhart

2,510,280

Charles Conway

1,626,150

Kimberly Gentile

--

Robert Berman

521,060
As Of  31 Dec 2017